The U.S. Supreme Court has once again stepped in to limit the influence of the conservative 5th U.S. Circuit Court of Appeals, this time by preserving nationwide access to the abortion pill mifepristone. The decision temporarily halted a May 1 ruling from the New Orleans-based appeals court that would have restricted telemedicine prescriptions and mail delivery of the medication. The case highlights the ongoing legal and political battle surrounding abortion rights in the United States following the Supreme Court’s 2022 decision allowing states to ban abortion.
Despite the Supreme Court’s current 6-3 conservative majority, the justices have repeatedly pushed back against rulings from the 5th Circuit, which oversees Louisiana, Texas, and Mississippi. Legal experts say the appeals court has become one of the nation’s most aggressive conservative judicial bodies, frequently issuing decisions that challenge federal policies on abortion, gun rights, immigration, and religious freedom.
The Supreme Court’s unsigned order paused the 5th Circuit’s restrictions while litigation continues. Only Justices Clarence Thomas and Samuel Alito publicly dissented. Analysts note that the 5th Circuit often advances rulings further to the political right than even the Supreme Court is willing to accept.
The abortion pill dispute stems from a challenge to a Biden-era FDA regulation allowing mifepristone to be prescribed remotely and shipped by mail. Judge Kyle Duncan of the 5th Circuit argued the policy undermined Louisiana’s abortion ban and lacked sufficient scientific justification. However, the Supreme Court previously overturned another 5th Circuit decision limiting access to mifepristone in 2024, ruling that anti-abortion groups lacked legal standing.
The 5th Circuit continues to play a major role in shaping national legal debates, with several controversial cases expected to reach the Supreme Court again in the coming months.


Rodrigo Duterte Makes First Public Appearance at ICC in 18 Months
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
U.S. Issues Cuba Health Alert as Illnesses Rise
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars
US Appeals Court Upholds Anthropic AI Supply Chain Ban
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
Paramount Skydance Faces $30 Million Film Penalty in Warner Bros. Deal
Colombia Extradites FARC Dissident Leader ‘Spider’ to US
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal
FDA Approves Mirum’s Atebrioz for Rare Bone Disorder FOP
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children
Appeals Court Rejects Trump Third-Country Deportation Policy
DaVoice Sues Perplexity AI Over Trade Secrets
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks
GSK Unveils $2.52 Billion Cost-Cutting Plan to Accelerate Drug Pipeline
Hengrui Shares Rise on $2.6 Billion Novo Nordisk Obesity Drug Deal 



